Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04554732 · ClinicalTrials.gov registry record · Early Phase 1

Keratinocyte Growth Factor- Hair Serum for the Prevention of Chemotherapy Induced Alopecia

A Early Phase 1 study of Alopecia and Hair Loss, sponsored by University of Arizona.

Completed
Registry status
Early Phase 1
Development phase
28
Enrollment target
1
Study location

NCT04554732: Completed Early Phase 1 study of Alopecia and Hair Loss, sponsored by University of Arizona.

NCT04554732 is a Early Phase 1 study of Alopecia and Hair Loss that has completed, run by University of Arizona. The registered enrollment target is 28 participants, below the 123-participant average among 13 other Alopecia trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04554732, a Early Phase 1 study of Alopecia and Hair Loss, has completed, sponsored by University of Arizona.

COMPLETED
Registry status
Early Phase 1
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

Primary aim is to provide a preliminary assessment of the efficacy of the investigational topical formula, KGF-HS, as a prophylactic treatment for chemotherapy induced alopecia. Hypothesis: KGF-HS will result in less than 50% hair loss by the end of 4 cycles of chemotherapy. The investigators will evaluate hair loss using the CTCAE (Common Terminology Criteria for Adverse Events) v4.0 alopecia grading scale.

Primary Outcome

Hypothesis: KGF-HS will result in less than 50% hair loss by the end of 4 cycles of chemotherapy. We will evaluate hair loss using the CTCAE (Common Terminology Criteria for Adverse Events) v4.0 alopecia grading scale: Grade 1 = Hair loss of \<50% of normal; Grade 2 = Hair loss of \>50% of normal.

Interventions

  • DRUG Keratinocyte growth factor

Study Locations (1)

Arizona

  • University of Arizona - Tucson

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2020-04-27
Est. Completion 2022-06-24
Phase Early Phase 1
University of Arizona

349 total trials

What the finished NCT04554732 record still lists

NCT04554732 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 123-participant average among 13 other Alopecia trials with a reported enrollment target (77% lower).

The record links to 4 conditions, with Alopecia appearing as the primary indexed condition, and to 1 intervention - of which Keratinocyte growth factor is the first listed.

NCT04554732 reports a single indexed study location in Arizona.

Frequently Asked Questions

What is clinical trial NCT04554732 about?

NCT04554732 is a clinical study titled "Keratinocyte Growth Factor- Hair Serum for the Prevention of Chemotherapy Induced Alopecia". Primary aim is to provide a preliminary assessment of the efficacy of the investigational topical formula, KGF-HS, as a prophylactic treatment for chemotherapy induced alopecia. Hypothesis: KGF-HS will result in less than 50% hair loss by the end of 4 cycles of chemotherapy. The investigators will ...

What is the current status of trial NCT04554732?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 28 participants. The study started on 2020-04-27. Estimated completion is 2022-06-24.

What conditions does trial NCT04554732 study?

This clinical trial studies the following conditions: Alopecia, Hair Loss, Chemotherapy-Induced Change, Alopecia Drugs.

What interventions are being tested in trial NCT04554732?

The interventions under investigation include: Keratinocyte growth factor (DRUG).

Who is sponsoring clinical trial NCT04554732?

This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04554732 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alopecia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04554732's enrollment target sits among peer trials

28 12th of 13 higher than 2 of 13 other Alopecia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alopecia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04554732, the US trial registry maintained by the National Library of Medicine. NCT04554732 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.